BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34768395)

  • 1. Serum Calretinin as a Biomarker in Malignant Mesothelioma.
    Zupanc C; Franko A; Štrbac D; Dodič Fikfak M; Kovač V; Dolžan V; Goričar K
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calretinin as a blood-based biomarker for mesothelioma.
    Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
    BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of genetic factors with serum calretinin levels in asbestos-related diseases.
    Zupanc C; Franko A; Strbac D; Kovac V; Dolzan V; Goricar K
    Radiol Oncol; 2023 Dec; 57(4):473-486. PubMed ID: 38038422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.
    Goricar K; Kovac V; Dodic-Fikfak M; Dolzan V; Franko A
    Radiol Oncol; 2020 Mar; 54(1):86-95. PubMed ID: 32187018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
    Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
    N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients.
    Raiko I; Sander I; Weber DG; Raulf-Heimsoth M; Gillissen A; Kollmeier J; Scherpereel A; Brüning T; Johnen G
    BMC Cancer; 2010 May; 10():242. PubMed ID: 20509881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
    Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
    Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
    Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide.
    Dipalma N; Luisi V; Di Serio F; Fontana A; Maggiolini P; Licchelli B; Mera E; Bisceglia L; Galise I; Loizzi M; Pizzigallo MA; Molinini R; Vimercati L
    Int J Biol Markers; 2011; 26(3):160-5. PubMed ID: 21928246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of plasma calretinin in patients with malignant pleural mesothelioma.
    Lehnert M; Weber DG; Taeger D; Raiko I; Kollmeier J; Stephan-Falkenau S; Brüning T; Johnen G;
    BMC Res Notes; 2020 Jul; 13(1):359. PubMed ID: 32727552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J; Musk AW; Robinson BW
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.
    Di Serio F; Fontana A; Loizzi M; Capotorto G; Maggiolini P; Mera E; Bisceglia L; Molinini R
    Clin Chem Lab Med; 2007; 45(5):634-8. PubMed ID: 17484626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual predictors of increased serum mesothelin in asbestos-exposed workers.
    Filiberti R; Marroni P; Mencoboni M; Mortara V; Caruso P; Cioè A; Michelazzi L; Merlo DF; Bruzzone A; Bobbio B; Del Corso L; Galli R; Taveggia P; Dini G; Spigno F
    Med Oncol; 2013 Mar; 30(1):422. PubMed ID: 23277285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
    Johnen G; Burek K; Raiko I; Wichert K; Pesch B; Weber DG; Lehnert M; Casjens S; Hagemeyer O; Taeger D; Brüning T;
    Sci Rep; 2018 Sep; 8(1):14321. PubMed ID: 30254313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.